Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telescope InnovationsTELIF +0.68%30 Cash Ratio is 0.94 as of May. 2026, which is 81% above its 10-year median of 0.52. GuruFocus rates TELIF with a GF Score™ of 30/100 and a GF Value™ of $0.39 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,381 Biotechnology companies, Telescope Innovations ranks worse than 74.22% on this metric.
Telescope Innovations has a Cash Ratio of 0.94. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Telescope Innovations's Cash Ratio or its related term are showing as below:
TELIF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.52 Max: 13.34
Current: 0.94
During the past 7 years, Telescope Innovations's highest Cash Ratio was 13.34. The lowest was 0.01. And the median was 0.52.
TELIF's Cash Ratio is ranked worse than 74.22% of 1381
companies
in the Biotechnology industry
Industry Median: 2.96
vs TELIF: 0.94
Telescope Innovations (OTCPK:TELIF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Telescope Innovations's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telescope Innovations (TELIF) has a Cash Ratio of 0.94 as of May. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Telescope Innovations and its competitors. This is 81% above median its historical median of 0.52. Over the past decade, Telescope Innovations' Cash Ratio has ranged from 0.01 to 13.34. According to the industry distribution chart, Telescope Innovations ranks #1025 out of 1381 companies in the Biotechnology industry, placing it in the top 74.2%.
Is Telescope Innovations' Cash Ratio too high?
Telescope Innovations' current Cash Ratio of 0.94 is 81% above median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 13.34. The Biotechnology industry median Cash Ratio is 2.96. Telescope Innovations' value of 0.94 is 68.2% below this industry median. Based on the distribution chart, Telescope Innovations ranks #1025 out of 1381 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Telescope Innovations has a GF Score™ of 30/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #1025 out of 1381 companies for Cash Ratio. This places Telescope Innovations in the lower half of its industry. The industry median Cash Ratio is 2.96. Telescope Innovations' value of 0.94 is 68.2% below this benchmark. Historically, Telescope Innovations' own Cash Ratio has ranged from 0.01 to 13.34 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 2.96, Telescope Innovations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current Cash Ratio of 0.94 is 68.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Telescope Innovations and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current Cash Ratio is 0.94, which is 81% above median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.39, compared to a current price of $0.31 — trading 20.5% below its estimated fair value. The current Cash Ratio is 0.94, which is 81% above median its 10-year median of 0.52 and 68.2% below the Biotechnology industry median of 2.96. Telescope Innovations' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current Cash Ratio is 0.94 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be undervalued.
The current stock price of $0.31 is trading 20.5% below its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Modestly Undervalued.
Key valuation signals for TELIF:
Cash Ratio: 0.94 (81% above median its 10-year median of 0.52)
GF Value™: $0.39 vs. price of $0.31 (20.5% below fair value)
Industry Position: 68.2% below the Biotechnology median (#1025 of 1381)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
30GF Score
Get the complete analysis for TELIF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
